Neuronetics (STIM) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $18.5 million, up 4% year-over-year, driven by growth in U.S. treatment sessions and NeuroStar system sales, with 49 systems shipped.

• Net loss widened to $13.3 million ($0.44/share) in Q3 2024, compared to $9.4 million ($0.33/share) in Q3 2023, impacted by a $4.4 million debt extinguishment loss and higher G&A costs.

• Shareholders approved the Greenbrook TMS acquisition, expected to close in Q4 2024, positioning the company for scale, cost synergies, and accelerated profitability.

• Strategic reorganization in November 2024 reduced workforce by 10%, targeting $3.5 million in annualized cash savings and $20 million in annualized cost synergies.

• Over 188,000 global patients treated with 6.9 million NeuroStar sessions; FDA clearance in March 2024 expanded the addressable U.S. market by 35% to 29.3 million adults and adolescents.

Financial highlights

• Gross margin improved to 75.6%–76% in Q3 2024 from 65.8%–66% year-over-year, driven by favorable product mix and absence of prior one-time costs.

• Operating expenses rose 5% to $21.7 million in Q3 2024, mainly due to transaction-related and G&A costs.

• Cash and equivalents stood at $20.9 million as of September 30, 2024, with total assets of $74.1 million and accumulated deficit of $407.1 million.

• EBITDA for Q3 2024 was $(11.6) million, compared to $(7.7) million in Q3 2023.

• Cost of revenues fell 26% year-over-year in Q3 2024, supporting margin expansion.

Outlook and guidance

• Q4 2024 worldwide revenue expected at $19–$20 million; full-year 2024 guidance set at $71–$72 million.

• Full-year standalone operating expenses projected at $81–$82 million, excluding $2 million in pre-close transaction costs.

• Cash flow break-even targeted by Q2–Q3 2025, with profitability prioritized over top-line growth.

• Management expects further market expansion, especially in adolescent and international markets.